Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.
NEW YORK (GenomeWeb) – Arcturus Therapeutics has announced that it has added a second drug candidate to its transthyretin-mediated amyloidosis (ATTR) program.
Alnylam Pharmaceuticals last month announced that it has received a $7 million milestone payment from Genzyme based upon its positive data from a phase II trial of the TTR-mediated amyloidosis treatment patisiran, formerly known as ALN-TTR02.
Alnylam Pharmaceuticals this week announced positive data from a phase II trial of its TTR-mediated amyloidosis drug patisiran, formerly ALN-TTR02, showing that the drug triggered "robust and statistically significant" inhibition of its target protein.
Alnylam Pharmaceuticals this week provided an update on its flagship TTR-mediated amyloidosis drug ALN-TTR02, stating that it has begun enrollment in an open-label extension study of a recently completed phase II trial and unveiling the compound's international nonproprietary nam
Oct 3, 2013
Sep 26, 2013
May 30, 2013
May 9, 2013
Mar 21, 2013
Jan 10, 2013
Jan 3, 2013
Oct 25, 2012